Sir Andrew Dillon, chief executive of Nice, said: “Our increased confidence in the benefits and costs associated with the use of the three drugs for treating mild and moderate stages of the disease has enabled us to make a positive recommendation for their use in mild disease.
via ft.com
The National Institute for Health and Clinical Excellence, will on Thursday issue draft guidance calling for the National Health Service to pay for prescriptions of donepezil, galantamine and rivastigmine, as well as the use of memantine for severe and some moderate Alzheimer’s
No comments:
Post a Comment